Oncologylive News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Oncologylive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Oncologylive Today - Breaking & Trending Today
Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development. ....
Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism. ....
Although relapsed/refractory follicular lymphoma remains a difficult- to-treat disease, the emergence of anti-CD20 monoclonal antibodies in recent years has signaled progress, including the 2019 FDA approval of rituximab plus lenalidomide. ....
Addressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies. ....
An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes. ....